Among the clinical characteristics studied, including patient age, the International Staging System (ISS), anemia, and the levels of β2-microglobulin, albumin, creatinine, plasmacytes, lactate dehydrogenase (LDH), and serum calcium, we found that hyper-β2-microglobulinemia, anemia, and the higher abundance of circulating plasmacytes shortened the time to MM progression (p = 0.009, p = 0.02, and p = 0.08, respectively), thus indicating their predictive significance and enrollment of suitable patients (Figure 6). The gene discussed is ALB; the disease is anemia.